Vaccine factory inspected amid EU dispute with AstraZeneca
Belgian health authorities have inspected a pharmaceutical factory located in Belgium to find out whether the expected delays in the deliveries of AstraZeneca’s coronavirus vaccine are due to production issues
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Belgian health authorities announced Thursday they have inspected a pharmaceutical factory in Belgium to find out whether expected delays in the deliveries of AstraZeneca’s coronavirus vaccine are due to production issues.
The European Commission had asked the Belgian government to inspect the factory amid a heated public dispute between the 27-nation bloc and the Anglo-Swedish drugmaker. EU officials are under tremendous political pressures because the bloc's vaccine rollout has been much slower than that of Israel or Britain.
The Novasep’s factory in the town of Seneffe is part of the European production chain for the Oxford-AstraZeneca coronavirus vaccine.
AstraZeneca said last week that it planned to cut initial deliveries in the EU to 31 million doses from the 80 million it had planned due to reduced yields from its manufacturing plants in Europe. The EU claimed Wednesday that it will receive even less than that — just one quarter of the doses that member nations were supposed to get during January-March 2021.
According to the EU, the Belgian factory is one of four AstraZeneca sites included in the contract sealed by the European Commission and the company to produce vaccines for the EU market.
“The Novasep teams worked hard to meet its obligations to AstraZeneca with unprecedented speed and commitment," Novasep said in a statement to The Associated Press. “Manufacturing the COVID-19 vaccine is a pioneering process in terms of scale, complexity and quantity. We have worked closely with AstraZeneca and conducted regular and coordinated reviews of the production processes to ensure the active drug substance was delivered on time and met the highest standards for quality and stability."
France Dammel, a spokesperson for Belgium's health minister, said experts from the federal medicine agency inspected the Novasep site. They will now work with Dutch, Italian and Spanish experts before delivering a report in the coming days.
The EU said it expects to deliver the full amount on time and has threatened to put export inspections on all vaccines made in its territory. Stella Kyriakides, the European Commissioner for health and food safety, said AstraZeneca should provide vaccines from its U.K. facilities if it it is unable to meet commitments from factories in the EU.
After a third round of talks with AstraZeneca aimed at resolving the dispute on Wednesday evening, Kyriakides regretted the “continued lack of clarity on the delivery schedule” and urged AstraZeneca to come up with a clear plan for a quick delivery of the doses reserved by the EU for the first quarter.
A spokesman for AstraZeneca said after the meeting that the company has “committed to even closer coordination to jointly chart a path for the delivery of our vaccine over the coming months as we continue our efforts to bring this vaccine to millions of Europeans at no profit during the pandemic.”
The EU, which has 450 million people, has signed deals for six different vaccines, but so far regulators have only authorized the use of two, one made by Pfizer and another by Moderna. The EU’s drug regulator will consider the AstraZeneca vaccine on Friday.
___
Sylvain Plazy contributed to this story.
___
Follow all of AP’s pandemic coverage at:
https://apnews.com/hub/coronavirus-pandemic
https://apnews.com/hub/coronavirus-vaccine
https://apnews.com/UnderstandingtheOutbreak